Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Update marks the first MDMA-assisted therapy session at a Numinus clinic VANCOUVER, BC, March 30, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a mental healthcare company advancing innovative treatments and safe, evidence-based ... [Read]
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
VANCOUVER, BC, Feb. 28, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual ... [Read]
Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022
Dr. Devon Christie, Dr. Robin Carhart-Harris, Dr. Frederick Barrett and Tura Patterson will discuss “Psychedelic Research: Moving Beyond the Social and Political Stigma” VANCOUVER, BC, Feb. 10, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the ... [Read]
Numinus Appoints New Bioscience Advisors to Advance IP Development
Advisors lead their fields in patent law, nutraceuticals & ethnobotany VANCOUVER, BC, Feb. 1, 2022 – Numinus’s Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is ... [Read]
Numinus Wellness Inc. Graduates to the OTCQX Best Market
VANCOUVER, BC, Jan. 26, 2022 – Numinus Wellness Inc. (TSX: NUMI) (OTC:NUMIF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will ... [Read]
Numinus Wellness Inc. Reports Q1 2022 Results
Ended the quarter with a strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy ... [Read]
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus has received approvals from Health Canada and the Institutional Ethics Review Board VANCOUVER, BC, Jan. 19, 2022 – Numinus Wellness Inc. (TSXV:NUMI) (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased ... [Read]
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
The trial evaluates Numinus’ first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(“Numinus“), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally ... [Read]
Numinus to Host Q1 2022 Results Conference Call on January 13, 2022
VANCOUVER, BC, Jan. 5, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”) (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for ... [Read]
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a ... [Read]